1. Walley, T., & Breckenridge, A. (2008). Pharmacoeconomics Comes of Age?. Clinical Pharmacology & Therapeutics, 84. https://doi.org/10.1038/clpt.2008.122.
DOI: https://doi.org/10.1038/clpt.2008.122
2. Mahendrakar, A., Ajja, H., Sinwal, A., , I., , N., & Jain, P. (2024). Pharmacoeconomics in Healthcare By IJISRT. International Journal of Innovative Science and Research Technology (IJISRT). https://doi.org/10.38124/ijisrt/ijisrt24mar1293.
DOI: https://doi.org/10.38124/ijisrt/IJISRT24MAR1293
3. Tonin, F., Aznar-Lou, I., Pontinha, V., Pontarolo, R., & Fernandez‐Llimos, F. (2021). Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharmacy Practice, 19. https://doi.org/10.18549/PharmPract.2021.1.2302.
DOI: https://doi.org/10.18549/PharmPract.2021.1.2302
4. Carswell, C. (2008). Essentials of Pharmacoeconomics. PharmacoEconomics, 26, 1065. https://doi.org/10.2165/0019053-200826120-00008.
5. Froemming, S., Cold, J., & Wells, B. (1989). Pharmacoeconomic Evaluations in Medicine. , 23, 431 - 431. https://doi.org/10.1177/106002808902300517.
DOI: https://doi.org/10.1177/106002808902300517
6. Reeder, C. (1995). Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 52 19 Suppl 4, S5-8 . https://doi.org/10.1093/AJHP/52.19_SUPPL_4.S5.
7. Mauskopf, J. (2020). Budget Impact Analysis. Pharmacoeconomics. https://doi.org/10.1201/9780429491368.
8. Mauskopf, J., & Annemans, L. (2020). Budget Impact Analysis. Pharmacoeconomics. https://doi.org/10.1201/9780429491368-8.
DOI: https://doi.org/10.1201/9780429491368-8
9. Yumrukaya, L., Postma, P., Sözen-Şahne, B., & Yeğenoğlu, P. (2022). Recommendations on Pharmacoeconomic Guidelines for Turkey Considering Reference Countries: A scoping review. Health Policy and Technology. https://doi.org/10.1016/j.hlpt.2022.100682.
DOI: https://doi.org/10.1016/j.hlpt.2022.100682
10. O'Brien, B. (1995). Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?. Medical Care, 34.
11. O'Brien, B. (1996). Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?. Medical care, 34 12 Suppl, DS99-108 .
12. Henry, D., & Lopert, R. (1999). Pharmacoeconomics and policy decisions: the Australian health care system.. Clinical therapeutics, 21 5, 909-15 . https://doi.org/10.1016/S0149-2918(99)80012-5.
DOI: https://doi.org/10.1016/S0149-2918(99)80012-5
13. Führlinger, S. (2006). [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].. Wiener medizinische Wochenschrift, 156 23-24, 612-8 .
DOI: https://doi.org/10.1007/s10354-006-0357-7
14. Cleemput, I., Van Wilder, P., Huybrechts, M., & Vrijens, F. (2009). Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 12 4, 441-9 . https://doi.org/10.1111/j.1524-4733.2008.00469.x.
DOI: https://doi.org/10.1111/j.1524-4733.2008.00469.x
15. Franken, M., Nilsson, F., Sandmann, F., Boer, A., & Koopmanschap, M. (2013). Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. PharmacoEconomics, 31, 781-797. https://doi.org/10.1007/s40273-013-0074-1.
DOI: https://doi.org/10.1007/s40273-013-0074-1
16. Garrison, P., Neumann, S., Erickson, P., Marshall, P., & Mullins, P. (2007). Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 10 5, 326-35 . https://doi.org/10.1111/J.1524-4733.2007.00186.X.
DOI: https://doi.org/10.1111/j.1524-4733.2007.00186.x
17. Meltzer, M. (2001). Introduction to health economics for physicians. The Lancet, 358, 993-998. https://doi.org/10.1016/S0140-6736(01)06107-4.
DOI: https://doi.org/10.1016/S0140-6736(01)06107-4
18. Hensher, M. (2023). Climate change, health and sustainable healthcare: The role of health economics.. Health economics. https://doi.org/10.1002/hec.4656.
DOI: https://doi.org/10.1002/hec.4656
19. Lange, S., & Vollmer, S. (2017). The effect of economic development on population health: a review of the empirical evidence. British Medical Bulletin, 121, 47–60. https://doi.org/10.1093/bmb/ldw052.
DOI: https://doi.org/10.1093/bmb/ldw052
20. Spiteri, J., & Von Brockdorff, P. (2019). Economic development and health outcomes: Evidence from cardiovascular disease mortality in Europe.. Social science & medicine, 224, 37-44 . https://doi.org/10.1016/j.socscimed.2019.01.050.
DOI: https://doi.org/10.1016/j.socscimed.2019.01.050
21. Sculpher, M., Claxton, K., & Pearson, S. (2017). Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 20 2, 234-239 . https://doi.org/10.1016/j.jval.2016.11.021.
DOI: https://doi.org/10.1016/j.jval.2016.11.021
22. Ochalek, J., Lomas, J., & Claxton, K. (2018). Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health, 3. https://doi.org/10.1136/bmjgh-2018-000964.
DOI: https://doi.org/10.1136/bmjgh-2018-000964
23. Cookson, R., Propper, C., Asaria, M., & Raine, R. (2016). Socio‐Economic Inequalities in Health Care in England. Fiscal Studies, 37, 371-403. https://doi.org/10.1111/J.1475-5890.2016.12109.
DOI: https://doi.org/10.1111/j.1475-5890.2016.12109
24. Dickman, S., Himmelstein, D., & Woolhandler, S. (2017). Inequality and the health-care system in the USA. The Lancet, 389, 1431-1441. https://doi.org/10.1016/S0140-6736(17)30398-7.
DOI: https://doi.org/10.1016/S0140-6736(17)30398-7
25. Johar, M., Soewondo, P., Pujisubekti, R., Satrio, H., & Adji, A. (2018). Inequality in access to health care, health insurance and the role of supply factors.. Social science & medicine, 213, 134-145 . https://doi.org/10.1016/j.socscimed.2018.07.044.
DOI: https://doi.org/10.1016/j.socscimed.2018.07.044
26. Mcintyre, D., Meheus, F., & Røttingen, J. (2017). What level of domestic government health expenditure should we aspire to for universal health coverage?. Health Economics, Policy and Law, 12, 125 - 137. https://doi.org/10.1017/S1744133116000414.
DOI: https://doi.org/10.1017/S1744133116000414
27. Mahumud, R. A., Alam, K., Dunn, J., & Gow, J. (2019). The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia. PLoS One, 14(10), e0223658.
DOI: https://doi.org/10.1371/journal.pone.0223658
28. Babela, R., Orsagh, A., Ricova, J., Lansdorp-Vogelaar, I., Csanadi, M., De Koning, H., & Reckova, M. (2022). Cost-effectiveness of colorectal cancer screening in Slovakia. European Journal of Cancer Prevention, 31(5), 415-421.
DOI: https://doi.org/10.1097/CEJ.0000000000000727
29. Reeves, P., Edmunds, K., Searles, A., & Wiggers, J. (2019). Economic evaluations of public health implementation-interventions: a systematic review and guideline for practice. Public Health, 169, 101-113.
DOI: https://doi.org/10.1016/j.puhe.2019.01.012
30. Organised by: EUPHA-ECO, EUPHA-HTA, & Chair persons: João Vasco Santos (EUPHA-ECO), Vanessa Gorasso (EUPHA-ECO). (2022). 4. G. Workshop: Economic evaluations of public health interventions: from case studies to next methodological steps. European Journal of Public Health, 32(Supplement_3), ckac129-234.
DOI: https://doi.org/10.1093/eurpub/ckac129.234
31. Roberts, S. L. E., Healey, A., & Sevdalis, N. (2019). Use of health economic evaluation in the implementation and improvement science fields—a systematic literature review. Implementation Science, 14(1), 72.
DOI: https://doi.org/10.1186/s13012-019-0901-7
32. Frew, E., & Breheny, K. (2019). Methods for public health economic evaluation: A Delphi survey of decision makers in English and Welsh local government. Health Economics, 28(8), 1052-1063.
DOI: https://doi.org/10.1002/hec.3916
33. Reeder, C. (1995). Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 52 19 Suppl 4, S5-8 . https://doi.org/10.1093/AJHP/52.19_SUPPL_4.S5.
DOI: https://doi.org/10.1093/ajhp/52.19_Suppl_4.S5
34. Arenas-Guzmán, R., Tosti, A., Hay, R., & Haneke, E. (2005). Pharmacoeconomics – an aid to better decision‐making. Journal of the European Academy of Dermatology and Venereology, 19. https://doi.org/10.1111/j.1468-3083.2005.01285.x.
DOI: https://doi.org/10.1111/j.1468-3083.2005.01285.x
35. Carswell, C. (2008). Essentials of Pharmacoeconomics. PharmacoEconomics, 26, 1065. https://doi.org/10.2165/0019053-200826120-00008.
DOI: https://doi.org/10.2165/0019053-200826120-00008
36. Gold, M. R., Stevenson, D., & Fryback, D. G. (2002). 36.
DOI: https://doi.org/10.1016/S0896-6273(02)00971-6
37. HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annual review of public health, 23(1), 115-134.
DOI: https://doi.org/10.1146/annurev.publhealth.23.100901.140513
38. Rios-Diaz, A. J., Lam, J., Ramos, M. S., Moscoso, A. V., Vaughn, P., Zogg, C. K., & Caterson, E. J. (2016). Global patterns of QALY and DALY use in surgical cost-utility analyses: a systematic review. PloS one, 11(2), e0148304.
DOI: https://doi.org/10.1371/journal.pone.0148304
39. Robinson, L. A. (2024). Ethics and Benefit–Cost Analysis: Introduction to the Special Issue. Journal of Benefit-Cost Analysis, 15(S1), 1-5.
DOI: https://doi.org/10.1017/bca.2025.1
40. Hansson, S. O. (2007). Philosophical problems in cost–benefit analysis. Economics & Philosophy, 23(2), 163-183.
DOI: https://doi.org/10.1017/S0266267107001356
41. Kelman, S. (2013). Cost-benefit analysis: an ethical critique. In Readings in risk (pp. 129-138). RFF Press.
42. Rowell, A. (2021). Ethical Choices Inside Regulatory Cost-Benefit Analysis. Geo. JL & Pub. Pol'y, 19, 693.
DOI: https://doi.org/10.2139/ssrn.3944299
43. Briggs, A. H., & O'Brien, B. J. (2001). The death of cost‐minimization analysis?. Health economics, 10(2), 179-184.
DOI: https://doi.org/10.1002/hec.584
44. Hughes, D. (2012). Pharmacoeconomics.. British journal of clinical pharmacology, 73 6, 968-72 . https://doi.org/10.1111/j.1365-2125.2012.04247.x.
DOI: https://doi.org/10.1111/j.1365-2125.2012.04247.x
45. Gamal, M., Sedrak, A., Elsisi, G., Elagamy, A., Seyam, A., Eldebeiky, M., & Eldessoki, R. (2024). National Recommendations for Pharmacoeconomic Evaluations Reporting for Reimbursement and Procurement of New Pharmaceutical Applications in Egypt. Global Journal on Quality and Safety in Healthcare, 7, 216 - 223. https://doi.org/10.36401/JQSH-24-12.
DOI: https://doi.org/10.36401/JQSH-24-12
46. Angelis, A., Lange, A., & Kanavos, P. (2017). Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. The European Journal of Health Economics, 19, 123 - 152. https://doi.org/10.1007/s10198-017-0871-0.
DOI: https://doi.org/10.1007/s10198-017-0871-0
47. Marušáková, E., & Bielik, J. (2013). Application of Health Technology Assessment and Pharmacoeconomics in the Decision-Making Process in Selected Eu Member States. Value in Health, 16. https://doi.org/10.1016/J.JVAL.2013.08.1994.
DOI: https://doi.org/10.1016/j.jval.2013.08.1994
48. Sharma, D., Aggarwal, A., Downey, L., & Prinja, S. (2021). National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison. PharmacoEconomics Open, 5, 349 - 364. https://doi.org/10.1007/s41669-020-00250-7.
DOI: https://doi.org/10.1007/s41669-020-00250-7
49. Yang, B. (2012). The Future of Health Technology Assessment in Healthcare Decision Making in Asia. PharmacoEconomics, 27, 891-901. https://doi.org/10.2165/11310280-000000000-00000.
DOI: https://doi.org/10.2165/11310280-000000000-00000
50. Tilson, L., O'Leary, A., Usher, C., & Barry, M. (2012). Pharmacoeconomic Evaluation in Ireland. PharmacoEconomics, 28, 307-322. https://doi.org/10.2165/11318790-000000000-00000.
DOI: https://doi.org/10.2165/11318790-000000000-00000
51. Lamrock, F., McCullagh, L., Tilson, L., & Barry, M. (2020). A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland. The European Journal of Health Economics, 21, 895 - 901. https://doi.org/10.1007/s10198-020-01181-0.
DOI: https://doi.org/10.1007/s10198-020-01181-0
52. Eandi, M. (2023). The Importance of the Pharmacoeconomic Analyses in Drug Negotiation. A Farewell Editorial. Farmeconomia. Health economics and therapeutic pathways. https://doi.org/10.7175/fe.v24i1.1547.
DOI: https://doi.org/10.7175/fe.v24i1.1547
53. Oral, M., & Özçelikay, G. (2017). Ethical Overview of Pharmaceutical Industry Policies in Turkey from Various Perspectives. Turkish Journal of Pharmaceutical Sciences, 14, 264 - 273. https://doi.org/10.4274/TJPS.88598.
DOI: https://doi.org/10.4274/tjps.88598
54. Main, C., Schäfer, C., & Kanavos, P. (2025). From Vision to Reality: The EU’s Pharmaceutical Reforms and the Path to Improved Access. PharmacoEconomics-Open, 9(3), 331-339.
DOI: https://doi.org/10.1007/s41669-024-00556-w
55.Martins, S. F., van Mil, J. F., & Da Costa, F. A. (2015). The organizational framework of community pharmacies in Europe. International journal of clinical pharmacy, 37(5), 896-905.
DOI: https://doi.org/10.1007/s11096-015-0140-1
56.Kriegner, S., Ottersen, T., Røttingen, J. A., & Gopinathan, U. (2020). Promoting intersectoral collaboration through the evaluations of public health interventions: insights from key informants in 6 European countries. International Journal of Health Policy and Management, 10(2), 67.
DOI: https://doi.org/10.34172/ijhpm.2020.19
57.Alzarea, A., Khan, Y., Alanazi, A., Butt, M., Almalki, Z., Alahmari, A., Alsahali, S., & Mallhi, T. (2022). Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries. International Journal of Environmental Research and Public Health, 19. https://doi.org/10.3390/ijerph19137862.
DOI: https://doi.org/10.3390/ijerph19137862
58. Drummond, M., & Banta, D. (2009). Health technology assessment in the United Kingdom. International Journal of Technology Assessment in Health Care, 25, 178 - 181. https://doi.org/10.1017/S0266462309090618.
DOI: https://doi.org/10.1017/S0266462309090618
59. Akehurst, R. (2010). Health technology assessment in the United Kingdom.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 13 Suppl 1, S4-5 . https://doi.org/10.1111/j.1524-4733.2010.00745.x.
DOI: https://doi.org/10.1111/j.1524-4733.2010.00745.x
60. Anderson, M., Drummond, M., Taylor, D., Mcguire, A., Carter, P., & Mossialos, E. (2022). Promoting innovation while controlling cost: The UK's approach to health technology assessment.. Health policy. https://doi.org/10.1016/j.healthpol.2022.01.013.
DOI: https://doi.org/10.1016/j.healthpol.2022.01.013
61. Li, Y., Mai, H., Trudeau, M., Mittmann, N., Chiasson, K., Chan, K., & Cheung, M. (2020). Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.. Current oncology, 27 5, e495-e500 . https://doi.org/10.1200/jco.2020.38.15_suppl.e14133.
DOI: https://doi.org/10.3747/co.27.6489
62. Meyers, D., Jenei, K., Chisamore, T., & Gyawali, B. (2021). Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.. JAMA internal medicine. https://doi.org/10.1001/jamainternmed.2020.8588.
DOI: https://doi.org/10.1001/jamainternmed.2020.8588
63. Gulmez, S., Aydın, V., & Akıcı, A. (2020). Footprints of clinical pharmacology in Turkey: Past, present, and future.. Clinical therapeutics. https://doi.org/10.1016/j.clinthera.2019.12.014.
DOI: https://doi.org/10.1016/j.clinthera.2019.12.014
64. Fischer, K., & Stargardt, T. (2014). Early Benefit Assessment of Pharmaceuticals in Germany. Medical Decision Making, 34, 1030 - 1047. https://doi.org/10.1177/0272989X14546377.
DOI: https://doi.org/10.1177/0272989X14546377
65. Macaulay, R., & Mohamoud, Z. (2019). VP40 Increasing Divergence Of IQWiG & G-BA Benefit Assessments Over Time?. International Journal of Technology Assessment in Health Care, 35, 86 - 86. https://doi.org/10.1017/s026646231900312x.
DOI: https://doi.org/10.1017/S026646231900312X
66. Jakovljevic, M. (2016). Comparison of historical medical spending patterns among the BRICS and G7. Journal of Medical Economics, 19, 70 - 76. https://doi.org/10.3111/13696998.2015.1093493.
DOI: https://doi.org/10.3111/13696998.2015.1093493
67. Tsak, A., Chang, A., Cowling, K., Micah, A., Chapin, A., et al., (2019). Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050. Lancet (London, England), 393, 2233 - 2260. https://doi.org/10.1016/S0140-6736(19)30841-4.
DOI: https://doi.org/10.1016/S0140-6736(19)30841-4
68. Zhao, Y., Feng, H., Qu, J., Luo, X., , W., & Tian, J. (2018). A systematic review of pharmacoeconomic guidelines. Journal of Medical Economics, 21, 85 - 96. https://doi.org/10.1080/13696998.2017.1387118.
DOI: https://doi.org/10.1080/13696998.2017.1387118
69. Van Dongen, J., Alili, E., Varga, A., Morel, A., Ben, A., Khorrami, M., Van Tulder, M., & Bosmans, J. (2019). What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations?. Expert Review of Pharmacoeconomics & Outcomes Research, 20, 27 - 37. https://doi.org/10.1080/14737167.2020.1694410.
DOI: https://doi.org/10.1080/14737167.2020.1694410
70. Mason, J., & Mason, A. (2006). The generalisability of pharmacoeconomic studies: issues and challenges ahead.. PharmacoEconomics, 24 10, 937-45 .
DOI: https://doi.org/10.2165/00019053-200624100-00001
71. Dubois, D. (2010). Grand Challenges in Pharmacoeconomics and Health Outcomes. Frontiers in Pharmacology, 1. https://doi.org/10.3389/fphar.2010.00007.
DOI: https://doi.org/10.3389/fphar.2010.00007
72. Gianfrancesco, F., Wang, R., Mahmoud, R., & White, R. (2012). Methods for Claims-Based Pharmacoeconomic Studies in Psychosis. PharmacoEconomics, 20, 499-511. https://doi.org/10.2165/00019053-200220080-00001.
DOI: https://doi.org/10.2165/00019053-200220080-00001
73. Cookson, R., Drummond, M., & Weatherly, H. (2009). Explicit incorporation of equity considerations into economic evaluation of public health interventions. Health Economics, Policy and Law, 4, 231 - 245. https://doi.org/10.1017/S1744133109004903.
DOI: https://doi.org/10.1017/S1744133109004903
74. Ward, T., Mújica-Mota, R., Spencer, A., & Medina-Lara, A. (2021). Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review. PharmacoEconomics, 40, 45-64. https://doi.org/10.1007/s40273-021-01094-7.
DOI: https://doi.org/10.1007/s40273-021-01094-7
75. Rojewski, A., Bailey, S., Bernstein, S., Cooperman, N., Gritz, E., Karam-Hage, M., Piper, M., Rigotti, N., & Warren, G. (2018). Considering Systemic Barriers to Treating Tobacco Use in Clinical Settings in the United States.. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. https://doi.org/10.1093/ntr/nty123.
DOI: https://doi.org/10.1093/ntr/nty123
76. Garg, A., Panda, P., Neudecker, M., & Lee, S. (2020). Barriers to the access and utilization of healthcare for trafficked youth: A systematic review.. Child abuse & neglect, 104137 . https://doi.org/10.1016/j.chiabu.2019.104137.
DOI: https://doi.org/10.1016/j.chiabu.2019.104137
77. Mullins, D., Onwudiwe, N., De Araújo, G., Chen, W., Xuan, J., Tichopád, A., & Hu, S. (2014). Guidance Document: Global Pharmacoeconomic Model Adaption Strategies.. Value in health regional issues, 5, 7-13 . https://doi.org/10.1016/j.vhri.2014.02.006.
DOI: https://doi.org/10.1016/j.vhri.2014.02.006
78. Yagudina, R., Kulikov, A., Serpik, V., Borodin, A., & Vygodchikova, I. (2021). Patient Flows, Patient Distribution Computations and Medicines Accounting in the Pharmacoeconomic Models Through Procurement Perspective. ClinicoEconomics and Outcomes Research: CEOR, 13, 673 - 680. https://doi.org/10.2147/CEOR.S312986.
DOI: https://doi.org/10.2147/CEOR.S312986
79. Brodtmann, A., Darby, D., Oboudiyat, C., Mahoney, C. J., Le Heron, C., Panegyres, P. K., & Brew, B. (2023). Assessing preparedness for Alzheimer disease‐modifying therapies in Australasian health care systems. Medical Journal of Australia, 218(6).
DOI: https://doi.org/10.5694/mja2.51880
80. Heidebrink, J. L., & Paulson, H. L. (2024). Lessons learned from approval of aducanumab for Alzheimer's disease. Annual review of medicine, 75(1), 99-111.
DOI: https://doi.org/10.1146/annurev-med-051022-043645
81. Thussu, S., Naidu, A., Manivannan, S., & Grossberg, G. T. (2024). Profiling aducanumab as a treatment option for Alzheimer’s disease: An overview of efficacy, safety and tolerability. Expert Review of Neurotherapeutics, 24(11), 1045-1053.
DOI: https://doi.org/10.1080/14737175.2024.2402058
English
